BlackRock Investment Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

BlackRock Investment Management’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$17K	Hold	1,354	–	–	﹤0.01%	3437
2016 Q3	$25K	Hold	1,354	–	–	﹤0.01%	3337
2016 Q2	$14K	Sell	1,354 -26,235	-95%	-$515K	﹤0.01%	3501
2016 Q1	$521K	Buy	27,589 +352	+1%	+$6.77K	﹤0.01%	2887
2015 Q4	$725K	Buy	27,237 +113	+0.4%	+$3.92K	﹤0.01%	2809
2015 Q3	$1.24M	Sell	27,124 -965	-3%	-$36.4K	﹤0.01%	2443
2015 Q2	$904K	Buy	28,089 +5,266	+23%	+$153K	﹤0.01%	2846
2015 Q1	$726K	Buy	22,823 +81	+0.4%	+$2.74K	﹤0.01%	2747
2014 Q4	$860K	Sell	22,742 -100	-0.4%	-$2.75K	﹤0.01%	2645
2014 Q3	$603K	Buy	22,842 +634	+3%	+$16.8K	﹤0.01%	2870
2014 Q2	$657K	Buy	22,208 +4,780	+27%	+$155K	﹤0.01%	2888
2014 Q1	$645K	Buy	17,428 +95	+0.5%	+$3.6K	﹤0.01%	2813
2013 Q4	$718K	Sell	17,333 -213	-1%	-$8.34K	﹤0.01%	2741
2013 Q3	$930K	Buy	17,546 +1,105	+7%	+$64.4K	﹤0.01%	2498
2013 Q2	$878K	Buy	+16,441	New	+$821K	﹤0.01%	2469

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Investment Management's NAVB Position: Q4 2016 in Review

BlackRock Investment Management held its Navidea Biopharmaceuticals Inc. (NAVB) position steady in Q4 2016 at 1,354 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #3437.

BlackRock Investment Management first reported a position in NAVB in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.24M in Q3 2015. 55 funds tracked by Wall St. Rank hold NAVB as of Q4 2016.

BlackRock Investment Management held 1,354 shares of Navidea Biopharmaceuticals Inc. worth $17K as of Q4 2016.
BlackRock Investment Management left its Navidea Biopharmaceuticals Inc. share count unchanged in Q4 2016.
Navidea Biopharmaceuticals Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3437 holding.
BlackRock Investment Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Investment Management's Navidea Biopharmaceuticals Inc. position peaked at $1.24M in Q3 2015.
55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.